Recently, Petrazzuolo and colleagues showed that anaplastic lymphoma kinase (ALK) inhibition causes immunogenic cell damage through the upregulation of CALR in a panel of ALK-driven lymphoma cell lines [17]. The gene discussed is ALK; the disease is lymphoma.